Published in final edited form as:

J Labelled Comp Radiopharm. 2008 August 1; 51(9): 325–328. doi:10.1002/jlcr.1529.

Studies on Taxol® Biosynthesis. Preparation and Tritium Labeling of Biosynthetic intermediates by Deoxygenation of a Taxadiene Tetra-acetate Obtained from Japanese Yew

Tohru Horiguchi¹, Christopher D. Rithner¹, Rodney Croteau³, and Robert M. Williams^{1,2}

¹ Contribution from the Department of Chemistry, Colorado State University, Fort Collins, Colorado 80523, U.S.A.

²University of Colorado Cancer Center, Aurora, Colorado

³Institute of Biological Chemistry, Washington State University, Pullman, WA, 99164, U.S.A

SUMMARY

Taxa-4(20),11(12)-diene-5 α -acetate **5** and Taxa-4(20), 11(12)-diene-5 α -acetate, 10 β -ol **6**, have been identified as early stage intermediates involved in the biosynthesis of Taxol® (paclitaxel). Tritium-labeled **5** and **6** were successfully prepared by Barton deoxygenation using tri-*n*-butyltintritiide of the C-14-hydroxyl group of a taxoid obtained from Japanese Yew.

Keywords

Taxol®; biosynthesis; Japanese yew; tritiation

INTRODUCTION

Taxol® (**1**), first isolated from the bark of the Pacific Yew tree *Taxus brevifolia* Nutt.¹ is a powerful therapeutic drug for cancer chemotherapy.² It exhibits remarkably high cytotoxicity and strong antitumor activity against a range of cancer cell lines that are resistant to existing anticancer drugs.³ Unfortunately, the Pacific Yew is slow growing and is primarily found in environmentally sensitive areas of the Pacific Northwest and stripping the tree of its bark kills the yew. Alternative sources the drug have therefore become an important objective. A method that has proven viable is the semi-synthesis of Taxol® from 10-deacetylbaccatin III that can be isolated from the needles, a renewable source, of the European Yew, *Taxus baccata*.⁴ This has attenuated this problem somewhat, but as the drug becomes more widely adopted, particularly for use earlier in the course of cancer intervention and for new therapeutic applications, pressure on the Yew population is likely to increase worldwide. Alternative means of Taxol® production are therefore being vigorously pursued since cost and availability will continue to be significant issues. The commercial supply of Taxol® and semi-synthetic precursors will have to increasingly rely on biological methods of production ; (1) extraction from intact *Taxus* plants, (2) *Taxus* cell culture,⁵ or (3) genetically engineered microbial systems.⁶ In order to produce large quantities of Taxol® or a pharmacophoric equivalent by

Note. We observed that the radio chemical yields in these experiments were unexpectedly low. The gross activity of tritium gas trapped for two kinds of Barton deoxygenation protocols (see Experimental; **9** to **6b** and **10** to **5b**) was calculated as 0.76 mCi, which is 0.76% of the activity of the 100 mCi *n*-Bu₃Sn³H reagent employed. The gross radiochemical activity for the liquid waste was determined to be 26 mCi and the remainder of the theoretical 71 mCi resided in the solid waste. The reason for the low radiochemical yields may be rationalized by the slower reaction rate of the Sn-T bond cleavage relative to that of Sn-H due to a primary kinetic isotopic effect.

semi-synthetic or perhaps, by genetically engineered biosynthetic methods, it is essential to gain a better understanding of the detailed biosynthetic pathways in *Taxus brevifolia* and other related Taxol®-producing species. We have shown that the early steps in Taxol® biosynthesis involve: (1) the cyclization of geranylgeranyl pyrophosphate (**2**, GGPP) to afford taxa-4(5),11(12)-diene (**3**) catalyzed by taxadiene synthase;⁷ (2) the cytochrome P450 hydroxylation of taxa-4(5),11(12)-diene (**3**) to taxa-4(20),11(12)-diene-5 α -ol (**4**) catalyzed by taxadiene hydroxylase;⁸ (3) the acetylation of **4** to taxa-4(20),11(12)-diene-5 α -acetate (**5**) catalyzed by taxadienol acetyltransferase⁹; (4) the cytochrome P450 hydroxylation of **5** to taxa-4(20),11(12)-diene-5 α -acetate-10 β -ol (**6**) catalyzed by a 10 β -hydroxylase followed by a series of complex, and as yet not fully defined oxygenations (Scheme 1).^{10, 11}

Due to the very low yield of the intermediate metabolites that may be obtained from natural sources, we have relied heavily on synthetic **3**¹², **4**⁸ **5**⁸ and **6**¹³ as substrates from which *in vivo* and *in vitro* bioconversion strategies have been utilized to identify lightly oxygenated taxoids downstream of these substances. In this paper, we report the procedure for the preparation of radioisotopically labeled **5** and **6** that are useful substrates to probe further intermediate steps in the biosynthesis of Taxol®.

RESULTS and DISCUSSION

We have previously reported the preparation of taxa-4(20),11(12)-diene-5 α -acetate-10 β -ol (**6**) by Barton deoxygenation of the C-14-hydroxyl group of a differentially protected derivative of natural **2 α** , **5 α** , 10 β -triacetoxo-14 β -(2-methyl)-butyryloxytaxa-4(20), 11(12)-diene (**8**), a major taxoid metabolite isolated from Japanese Yew heartwood.^{13a} The synthetic protocol devised, was successfully optimized and applied to the preparation of ³H-labeled **6** (1.49 mCi, 0.75 % radiochemical yield) by the treatment of **9** with a mixture of *n*-Bu₃Sn³H (0.0056 to 0.11 eq. 50 mCi) and *n*-Bu₃SnH (2.0eq) (Scheme 2).

Next, the conversion of **6a** to **5** was investigated as illustrated in Scheme 3. Attempted acylation of the 10 β -hydroxy group of **6a** by treatment with PhOCSCl and various bases including triethylamine, 2,6-lutidine, and LHMDs proved unsuccessful. Fortunately, the conversion of **6a** to the corresponding xanthate ester (**10**) proceeded in a good yield (68%) and a Barton deoxygenation of **10** with a mixture of *n*-Bu₃Sn³H (0.064 to 0.13 eq., 50 mCi) and *n*-Bu₃SnH (1.0 eq.) successfully gave the desired isotopically labeled substrate **5** (0.53 mCi, 0.27 % as radiochemical yield) as the sole product.

In summary, we have successfully prepared selectively tritium-labeled taxoids **5** and **6**. Despite the relatively low radiochemical yields, the specific activities of these substrates are more than sufficient for conducting many bioconversion experiments. Utilization of these labeled taxoids is presently being explored to probe downstream steps in the biosynthesis of Taxol® and will be reported on in due course.

EXPERIMENTAL

Materials and Methods

n-Bu₃Sn³H (100 mCi in 100 μ l hexane, 15-30 Ci/mmol 0.00333 to 0.00666 mmol) was purchased from American Radiolabeled Chemicals, Inc. Other chemicals were purchased from commercial suppliers. The identity of intermediates and precursors were identified by comparison to un-labeled, authentic standards either by TLC and/or spectroscopic methods. Since the tritiation by *n*-Bu₃Sn³H produces an unknown amount of tritium gas, the head space of two reaction flasks for the two Barton deoxygenation runs was flushed gently with nitrogen gas through a series of five traps made of Erlenmeyer flasks containing excess cinnamic acid, Pd/Carbon in 100 mL of ethanol at 0 °C. A stopcock was attached between the second reaction

flask and the first Erlenmeyer flask, in addition, a balloon was attached at the end of the series of traps, as a safety precaution. The reactions were run for three hours, after which the nitrogen gas flow was stopped and the stopcock was shut. The mixtures in the trap flasks were stirred at room temperature for twelve hours and any evolved tritium gas was trapped by catalytic hydrogenation of cinnamic acid. The gross activity of tritium gas trapped for two runs of Barton deoxygenation was calculated as 0.76 mCi.

[2 α , 14 β -³H]-5 α -Acetoxy-10 β -hydroxytaxa-4 (20), 11(12)-diene (6b)

To a solution of **9** (23.3 mg, 0.0299 mmol) in toluene (1 mL), AIBN (cat.), *n*-Bu₃SnH (16 μ L, 0.0598 mmol) and *n*-Bu₃Sn³H (50 mCi, 0.00167 to 0.00333 mmol in 50 μ L hexane) were added. The mixture was stirred at reflux temperature for 3 h. The mixture was condensed and purified by chromatography (hexane 2 mL, hexane/ EtOAc 15:1 15 mL), yielding a crude compound (10.7 mg, 0.0225 mmol, 75%). The crude material was analyzed by TLC and immediately used for the next reaction without spectroscopic identification.

To a solution of the crude product obtained above (10.7 mg, 0.0225 mmol,) in THF (1 mL) were added TBAF (25 μ L, 0.25 mmol as 1M THF) and AcOH (1 drop). The mixture was stirred for 24 h. The mixture was diluted with EtOAc (20 mL) and washed with NH₄Cl aq (10 mL) and brine (5 mL). The EtOAc layer was dried over anhydrous Na₂SO₄, filtered, and the organic layer was condensed and purified by silica gel chromatography (hexane/ EtOAc 4:1, 15 mL), yielding ³H-labeled **6b** (7.2 mg, 0.0208 mmol, 92%) with a calculated activity of 72 mCi/mmol. [α]²⁰_D = +62 (*c* 0.0019, CHCl₃); IR (NaCl): 3420, 2932, 1734, 1647, 1448, 1369, 1240, 1200, 1140, 1106, 1000, 959, 944, 893, 756; ¹H NMR (500 MHz, CDCl₃) δ : 5.48 (1H, dd, *J* = 2.4 Hz, 2.9 Hz, H-5), 5.88 (1H, s, H-20), 4.93 (1H, dd, *J* = 5.4 Hz, 11.7 Hz, H-10), 4.69 (1H, s, H-20), 2.87 (1H, d, *J* = 5.4 Hz, H-3), 2.29 (1H, ddd, *J* = 4.4 Hz, 12.2 Hz, 18.6 Hz, H-13), 2.23 (1H, dd, *J* = 11.7 Hz, 14.7 Hz, H-9), 1.99 (1H, ddt, *J* = 2.9 Hz, 9.3 Hz, 14.6 Hz, H-14), 1.88 (1H, dt, *J* = 4.4 Hz, 13.7 Hz, H-7), 1.84 (1H, ddd, *J* = 2.9 Hz, 10.3 Hz, 18.6 Hz, H-13), 1.73 (3H, s, Me-18), 1.71 (3H, s, Ac), 1.66 (2H, m, H-6), 1.62 (1H, m, H-1), 1.60 (3H, s, Me-17), 1.56 (1H, m, H-2), 1.48 (1H, dd, *J* = 3.9 Hz, 11.7 Hz, H-2), 1.44 (1H, dd, *J* = 5.9 Hz, 14.6 Hz, H-9), 1.28 (1H, ddd, *J* = 4.9 Hz, 10.3 Hz, 14.2 Hz, H-14), 1.16 (3H, s, Me-16), 0.93 (1H, ddd, *J* = 1.5 Hz, 4.4 Hz, 12.7 Hz, H-7), 0.80 (1H, br. OH), 0.59 (3H, s, Me-19); ¹³C NMR (100 MHz, C₆D₆) δ : 169.20 (Ac), 151.36 (C4), 140.19 (C11), 133.73 (C12), 112.36 (C20), 76.76 (C5), 68.11 (C10), 48.53 (C9), 44.83 (C1), 39.42 (C8), 38.84 (C15), 36.80 (C3), 34.60 (C7), 32.74 (C16), 31.21 (C13), 29.02 (C2), 28.86 (C6), 26.27 (C17), 23.61 (C14), 22.30 (C19), 21.74 (Ac), 21.59 (C18).

Taxa-4(20), 11(12)-diene-10 β -S-methyl dithiocarboxy-5 α -acetate (10)

To a solution of **6a** (59.4 mg, 0.171 mmol) in THF (2 mL), LHMDS (188 μ L, 0.188 mmol, as 1M THF solution) was added at 0 °C. After being stirred for 10 min, CS₂ (0.25 mL) was added and the mixture was stirred for 2 h at rt. Then MeI (13 μ L, 0.21 mmol) was added and the mixture was stirred for 24 h at rt. The mixture was diluted into CH₂Cl₂ (15 mL) and washed with water. The organic layer was dried over Na₂SO₄, and concentrated *in vacuo*. The residue was purified by chromatography (CHCl₃/MeOH 20:1), yielding **10** (50.7 mg, 0.116 mmol, 68%). [α]²⁰_D = +2.0 (*c* 1.9, CHCl₃); ¹H NMR (400 MHz, CD₃CN) δ : 5.40 (dd, *J* = 4.7 Hz, 13.2 Hz, 1H, H-10), 5.27 (dd, *J* = 2.8 Hz, 3.0 Hz, 1H, H-5), 5.08 (s, 1H, H-20), 4.79 (s, 1H, H-20), 2.93 (d, *J* = 5.8 Hz, 1H, H-3), 2.41 (s, 3H, MeCS₂), 2.45-2.36 (m, 2H, H-9 and H-13), 2.18 (m, 1H, H-7), 2.06 (m, 1H, H-14), 2.04 (s, 3H, MeCO), 1.99 (s, 3H, Me-18), 1.96 (m, 1H, H-13), 1.82-1.70 (m, 3H, H-1 and H-6), 1.68 (ddd, *J* = 2.3 Hz, 6.0 Hz, 15.8 Hz, 1H, H-2), 1.60 (ddd, *J* = 1.9 Hz, 4.9 Hz, 15.8 Hz, 1H, H-2), 1.54 (dd, *J* = 4.7 Hz, 14.9 Hz, H-9), 1.39 (s, 3H, Me-16), 1.20 (m, 2H, H-7 and H-14), 1.05 (s, 3H, Me-17), 0.68 (ddd, *J* = 1.9 Hz, 4.9 Hz, 13.2 Hz, 1H, H-7), 0.59 (s, 3H, Me-19); ¹³C NMR (100 MHz, CD₃CN) δ : 190.87 (CS₂Me), 170.96 (MeCO), 152.13 (C4), 137.21 (C11), 136.90 (C12), 112.92 (C20), 77.44 (C5), 48.68 (C9),

45.59 (C1), 44.33 (C15), 41.63 (C8), 40.50 (C10), 37.90 (C3), 34.59 (C7), 32.29 (C17), 31.82 (C13), 29.54 (C2), 29.19 (C6), 27.04 (C16), 23.91 (C14), 22.47 (MeCO), 22.22 (C19 and C18), 13.84 (CS₂Me); HR-FABMAS (M⁺) calcd for C₂₄H₃₆O₃S₂ 436.2096, found 436.2106.

[10-³H]-Taxa-4(20), 11(12)-diene-5 α -acetate (5b)

To a solution of **10** (11.3 mg, 0.0259 mmol) in toluene (1 mL), AIBN (cat.), *n*-Bu₃SnH (7 μ L, 0.025 mmol) and *n*-Bu₃Sn³H (50 mCi, 0.00167 to 0.00333 mmol in 50 μ L hexane) were added. The mixture was stirred at reflux temperature for 3 h. The mixture was condensed and purified by chromatography (hexane/EtOAc 25:1; 26 mL), yielding **5b** (1.9 mg, 0.0057 mmol, 22%) with a calculated activity of 93 mCi/mmol.

[α]_D²⁰ = +71 (c 1.1, CHCl₃); ¹H NMR (400 MHz, C₆D₆) δ : 5.52 (dd, J = 2.8 Hz, 3.0 Hz, 1H, H-5), 5.10 (s, 1H, H-20), 4.71 (s, 1H, H-20), 3.17 (m, 1H, H-3), 2.79 (dt, J = 5.3 Hz, 13.6 Hz, 1H, H-10), 2.35 (m, 1H, H-13), 2.10 (dt, J = 4.9 Hz, 13.4 Hz, 1H, H-7), 2.08 (m, 1H, H-10), 2.00 (m, 1H, H-14), 1.96 (m, 1H, H-9), 1.87 (m, 1H, H-13), 1.81 (s, 3H, Me-18), 1.75 (s, 3H, MeCO), 1.75 (m, 1H, H-6), 1.65 (m, 2H, H-6 and H-1), 1.54 (dd, J = 3.6 Hz, 4.0 Hz, 2H, H-2), 1.31 (s, 3H, Me-16), 1.31 (m, 1H, H-14), 1.12 (s, 3H, Me-17), 1.11 (m, 1H, H-9), 0.87 (ddd, J = 1.9 Hz, 4.9 Hz, 13.2 Hz, 1H, H-7), 0.59 (s, 3H, Me-19); ¹³C NMR (100 MHz, C₆D₆) δ : 169.33 (Ac), 151.47 (C4), 137.75 (C11), 130.50 (C12), 111.91 (C20), 76.83 (C5), 44.19 (C1), 40.71 (C9), 40.19 (C8), 39.79 (C15), 37.73 (C3), 33.94 (C7), 31.39 (C16), 30.95 (C13), 28.97 (C6), 28.79 (C2), 25.96 (C17), 25.47 (C10), 23.50 (C14), 22.79 (C19), 21.81 (Ac), 21.77 (C18); HR-FABMAS (M⁺) calcd for C₂₂H₃₄O₂ 330.2549, found 330.2559.

Acknowledgments

We thank the National Institutes of Health (Grant CA70375 to R.M.W., and Grant CA55254 to R.C.) for financial support. We thank Prof. Takayuki Oritani (Laboratory of Applied Bioorganic Chemistry, Division of Life Science, Graduate School of Agricultural Science, Tohoku University, Japan) and Hida Ichii Ittoubori Kyoudou Kumiai of The Engraving Craftsman Association, Hida, Japan for the generous gift of the Japanese yew heartwood. We thank the Yamada Science Foundation and Japan Society for the Promotion of Science (JSPS) for fellowship support (to T.H.).

REFERENCES

1. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. J. Am. Chem. Soc 1971;93:2325–2327. [PubMed: 5553076]
2. a Suffness, M. Taxane anticancer agents: Basic science and current status. Georg, GI.; Chen, TT.; Ojima, I.; Vyas, DM., editors. American Chemical Society; Washington, DC: 1995. p. 1-17. b Suffness, M.; Wall, ME. Taxol: Science and applications. Suffness, M., editor. CRC Press; Boca Raton FL: 1995. p. 3-25. c Holmes, FA.; Kudelka, AP.; Kavanagh, JJ.; Huber, MH.; Ajani, JA.; Valero, V. Taxane anticancer agents: Basic science and current status. Georg, GI.; Chen, TT.; Ojima, I.; Vyas, DM., editors. American Chemical Society; Washington, DC: 1995. p. 31-57. d Golspiel BR. Pharmacotherapy 1997;17:110S–125S. [PubMed: 9322878] e Farina, V., editor. 'The Chemistry and Pharmacology of Taxol and its Derivatives'. Vol. 22. Pharmacochimistry Library; Elsevier; Amsterdam: 1995.
3. Paclitaxel is the generic name for Taxol®, a registered trademark of Bristol-Myers Squibb; because of its greater familiarity, the term "Taxol®" is used herein throughout.
4. a Holton, RA.; Biediger, RJ.; Boatman, PD. Taxol: Science and Applications. Suffness, M., editor. CRC Press, Inc.; Boca Raton, FL: 1995. p. 97-121. b Boa AN, Jenkins PR, Lawrence NJ. Recent Progress in the Synthesis of Taxanes. Contemp. Org. Synth 1994;47–75. c Denis J-N, Greene AE, Guénard D, Guéritte-Voegelein F, Mangatal L, Potier P. J. Am. Chem. Soc 1988;110:5917–5919.
5. Han K-H, Fleming P, Walker K, Loper M, Chilton WS, Mocek U, Gordon MP, Floss HG. Plant Science 1994;95:187–196. b Ketchum REB, Wherland L, Croteau RB. Plant Cell Rep 2007;26:1025–1033. [PubMed: 17333018]
6. a Stierle A, Strobel G, Stierle D. Science 1993;260:214–216. [PubMed: 8097061] b Metz AM, Haddad A, Worapong J, Long DM, Ford EJ, Hess WM, Strobel GA. Microbiol 2000;146:2079–2089. c Li JY,

- Sidhu RS, Ford EJ, Long DM, Strobel GA. *J. Ind. Microbiol. Biotech* 1998;20:259–264. d Stierle, A.; Stierle, D.; Strobel, G.; Bignami, G.; Grothaus, P. *Taxane Anticancer Agents*. American Chemical Society; 1995. p. 82-97. Chap. 6
7. a Hezari M, Croteau R. *Planta Medica* 1997;63:291–295. [PubMed: 9270370] b Walker K, Croteau R. *Phytochem* 2001;58:1–7. c Koepp AE, Hezari M, Zajicek J, Vogel BS, LaFever RE, Lewis NG, Croteau R. *J. Biol. Chem* 1995;270:8686–8690. [PubMed: 7721772] d Hezari M, Lewis NG, Croteau R. *Arch. Biochem. Biophys* 1995;322:437–444. [PubMed: 7574719] e Lin X, Hezari M, Koepp AE, Floss HG, Croteau R. *Biochem* 1996;35:2968–2977. [PubMed: 8608134] f Williams DC, Carroll BJ, Jin Q, Rithner CD, Lenger SR, Floss HG, Coates RA, Williams RM, Croteau R. *Chem. Biol* 2000;7:969–977. [PubMed: 11137819]
8. a Hefner J, Rubenstein SM, Ketchum REB, Gibson DM, Williams RM, Croteau R. *Chem. Biol* 1996;3:479–489. [PubMed: 8807878] b Rubenstein SM, Vazquez A, Williams RM. *J. Labeled Compd. Radiopharm* 2000;43:481–491.
9. a Walker K, Ketchum REB, Hezari M, Gatfield D, Goleniowski M, Barthol A, Croteau R. *Arch. Biochem. Biophys* 1999;364:273–279. [PubMed: 10190984] b Walker K, Schoendorf A, Croteau R. *Arch. Biochem. Biophys* 2000;374:371–380. [PubMed: 10666320]
10. Kaspera R, Croteau R. *Phytochem. Rev* 2006;5:433–444.
11. a Schoendorf A, Rithner CD, Williams RM, Croteau R. *Proc. Nat. Acad. Sci. USA* 2001;98:1501–1506. [PubMed: 11171980] b Jennewein S, Rithner CD, Williams RM, Croteau R. *Proc. Natl. Acad. Sci. USA* 2001;98:13595–13600. [PubMed: 11707604] c Ketchum REB, Croteau R. *Plant Metabolomics (in Biotechnology in Agriculture and Forestry)* 2006;57:291–309.
12. Rubenstein SM, Williams RM. *J. Org. Chem* 1995;60:7215–7223.
13. a Horiguchi T, Rithner CD, Croteau R, Williams RM. *J. Org. Chem* 2002;67:4901–4903. [PubMed: 12098303] b Horiguchi T, Rithner CD, Croteau R, Williams RM. *Tetrahedron* 2003;59:267–273. c Ketchum REB, Horiguchi T, Qiu D, Williams RM, Croteau RB. *Phytochem* 2007;68:335–341.

Scheme 1.

Early stages of Taxol® biosynthesis.

Scheme 2.
Synthesis of tritium-labeled **6**.

Scheme 3.
Preparation of tritium-labeled **5**.